BlackRock, Inc. Reports 4.2% Stake in Candel Therapeutics, Inc. (CADL) via Schedule 13G/A

On April 27, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a 4.2% ownership stake in Candel Therapeutics, Inc. (CADL). As of the event date of March 31, 2026, BlackRock beneficially owns 3,079,861 shares of common stock. The filing indicates that BlackRock has sole dispositive power over all 3,079,861 shares and sole voting power over 3,042,067 shares. This amendment marks an increase from a previously reported 0% position, though the total ownership remains below the 5% threshold, triggering the filing of Item 5 to report ownership of five percent or less of a class of securities. The shares were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. Various subsidiaries of BlackRock, Inc. are listed as having acquired the securities, with no single person's interest exceeding five percent of the total outstanding common shares.